🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

12+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 12 of 12 recruiting trials for “Adenocarcinoma of the oesophagus and oesophagogastric junction”

Phase 2RecruitingNCT07432295 ↗

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

🏥 I-Mab Biopharma US Limited📍 3 sites📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07059299 ↗

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

👨‍⚕️ Florian Lordick, Prof. Dr., Universitätsklinikum Leipzig📍 4 sites📅 Started Dec 2025View details ↗
Phase 1RecruitingNCT07284186 ↗

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

👨‍⚕️ Chief Medical Officer, Plexium, Inc.📍 10 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT06161818 ↗

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

👨‍⚕️ Bianca Mostert, MD, PhD, Erasmus Medical Centre📍 10 sites📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT06628310 ↗

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

👨‍⚕️ ABBVIE INC., AbbVie📍 49 sites📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT05563766 ↗

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

👨‍⚕️ David H Wang, MD PhD, VA Ann Arbor Healthcare System, Ann Arbor, MI📍 7 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06649474 ↗

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

👨‍⚕️ Marine JARY, MD, CHU Estaing de Clermont Ferrand/FRANCE📍 1 site📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06445972 ↗

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

👨‍⚕️ Medical Director, Merck Sharp & Dohme LLC📍 43 sites📅 Started Aug 2024View details ↗
Phase 1, PHASE2RecruitingNCT06324357 ↗

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

🏥 Boehringer Ingelheim📍 103 sites📅 Started Jun 2024View details ↗
Phase 1RecruitingNCT06266299 ↗

A Study of KK2269 in Adult Participants With Solid Tumors

🏥 Kyowa Kirin Co., Ltd.📍 11 sites📅 Started Jan 2024View details ↗
Phase 1, PHASE2RecruitingNCT06005493 ↗

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

🏥 AstraZeneca📍 25 sites📅 Started Jul 2023View details ↗
RecruitingNCT04290806 ↗

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

👨‍⚕️ Tobias Dechow, Prof., Ravensburg📍 1 site📅 Started Dec 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →